Neuraxis

Neuraxis CROIC

The Cash Return on Invested Capital (CROIC) of Neuraxis (NRXS) as of Nov 22, 2026 is -169.39 %. In the previous year, Cash Return on Invested Capital (CROIC) was -241.07 % — a change of -29.73% (higher).

CROIC

-169.39 %

YoY

-29.73%

Last updated:

Cash Return on Invested Capital (CROIC) of Neuraxis is 2025 -169.39 % . Cash Return on Invested Capital (CROIC) of Neuraxis was 2024 -241.07 % . It decreases by -29.73% higher compared to the previous year.

The Neuraxis CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2020
-213.12 USD
Jan 1, 2021
578.62 USD
Jan 1, 2022
47.42 USD
Jan 1, 2023
573.86 USD
Jan 1, 2024
-241.07 USD
Jan 1, 2025
-169.39 USD
The Neuraxis CROIC history
YEARCROICYoY
-169.39 %-29.73%
-241.07 %-142.01%
573.86 %+1,110.09%
47.42 %-91.80%
578.62 %-371.50%
-213.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Cash Return on Invested Capital (CROIC) of Neuraxis is -169.39 % in 2025.

Cash Return on Invested Capital (CROIC) of Neuraxis changed from -241.07 % to -169.39 %, representing a -29.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis